EU okays Roche's new anaemia drug Mircera

(Reuters) - ZURICH, July 26 - Swiss-based pharma firm Roche Holding AG said on Thursday the European Commission had approved its drug Mircera to treat anaemia associated with chronic kidney disease.



The potential blockbuster drug belongs to a class of medicines known as erythropoiesis-stimulating agents. They are used to boost red blood cells in anaemia patients to help avoid the need for blood transfusions.


Read more at Reuters.com Market News

European Stocks Advance; SAP, Roche, Vodafone, BHP Billtion Pace the Gains

(Bloomberg) -- European stocks rose for the first
time in three days after profit from SAP AG and Roche Holding AG
beat analysts' estimates, boosting prospects for earnings growth.

Vodafone Group Plc gained after the world's largest mobile-
phone company said it added more subscribers than analysts
anticipated. BHP Billiton Ltd. and Anglo American Plc led mining
stocks higher as copper rallied for a second day in Asia.


Read more at Bloomberg Stocks News

Roche, SAP, Ericsson Earnings, Germany's ZEW Index: European Week Ahead

(Bloomberg) -- Earnings from Roche Holding AG, the
world's biggest maker of cancer medicine, SAP AG, the largest
global maker of business-management software, and Ericsson AB,
the No. 1 maker of wireless phone networks, may move stock
markets next week.

Data on German investor confidence from the ZEW Center for
European Economic Research in Mannheim may also affect markets.


Read more at Bloomberg Stocks News

Alnylam, Boeing, LaBranche, Lexmark, Schnitzer Steel: U.S. Equity Movers

(Bloomberg) -- The following is a list of companies
whose shares are having unusual price changes in U.S. exchanges
today. Stock symbols are in parentheses after company names.
Share prices are as of 9:35 a.m. New York time.

Alnylam Pharmaceuticals Inc. (ALNY US) rose $8.30, or 55
percent, to $23.50. Roche Holding AG (ROG VX), the world's
biggest maker of cancer medicines, may pay as much as $1 billion
for rights to Alnylam technology that may allow the companies to
find new tumor, liver and breathing treatments.


Read more at Bloomberg Stocks News